Synthesis of highly cytotoxic tiazofurin mimics bearing a 2,3-anhydro function in the furanose ring

Tetrahedron

Volumn 65, Issue 36, 2009, Pages 7637-7645

  Popsavin, Mirjana ^a   Spaić, Saša ^a   Svirčev, Miloš ^a   Kojić, Vesna ^b   Bogdanović, Gordana ^b   Pejanović, Vjera ^a   Popsavin, Velimir ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b Oncology Institute of Vovodina   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,3 ANHYDRO BETA RIBOFURANOSYL)THIAZOLE 4 CARBOXAMIDE; 2 (2,5:3,4 DIANHYDRO 1 DEOXY DEXTRO ALLITOL 1 C YL)THIAZOLE 4 CARBOXAMIDE; 2 (2,5:3,4 DIANHYDRO 1 DEOXY DEXTRO ALTRITOL 1 C YL)THIAZOLE 4 CARBOXAMIDE; BROMINE DERIVATIVE; C NUCLEOSIDE; CYTOTOXIC AGENT; DOXORUBICIN; GLUCOSE; PYRUVIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; THIOAMIDE; TIAZOFURIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTALLOGRAPHY; CYCLOADDITION; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; POLYMERIZATION; PRIORITY JOURNAL;

EID: 68049100387     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2009.06.100     Document Type: Article

References (61)

1. For recent reviews on the chemistry of C-nucleosides, see:
2. Dolzhenko A.V., Dolzhenko A.V., and Chui W.K. Heterocycles 75 (2008) 1575
3. Merino P., Tejero T., and Delso I. Curr. Med. Chem. 15 (2008) 954
4. Enguehard-Gueiffier C., and Gueiffier A. Mini-Rev. Med. Chem. 7 (2007) 888
5. Wellington K.W., and Benner S.A. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1309
6. Wu Q., and Simons C. Synthesis (2004) 1533
7. Pankiewicz K.W., Watanabe K.A., Lesiak-Watanabe K., Goldstein B.M., and Jayaram H.N. Curr. Med. Chem. 9 (2002) 733
8. Lamberth C. Org. Prep. Proced. Int. 34 (2002) 149
9. For a brief overview of the biological and clinical impact of tiazofurin, see:. Grifantini M. Curr. Opin. Invest. Drugs 1 (2000) 257
10. Malek K., Boosalis M., Waraska K., Mitchell B.S., and Wright D.G. Leukemia Res. 28 (2004) 1125
11. Wright D.G., Boosalis M., Malek K., and Waraska K. Leukemia Res. 28 (2004) 1137
12. Wright D.G., Boosalis M.S., Waraska K., Oshry L.J., Weintraub L.R., and Vosburgh E. Anticancer Res. 16 (1996) 3349
13. Tricot G., and Weber G. Anticancer Res. 16 (1996) 3341
14. Weber G., Nagai M., Natsumeda Y., Eble J.N., Jayaram H.N., Paulik E., Zhen W.N., Hoffman R., and Tricot G. Cancer Commun. 3 (1991) 61
15. For reviews on recent progress in the development of new drugs based on inhibition of IMP dehydrogenase, see:
16. Shu Q., and Nair V. Med. Res. Rev. 28 (2008) 219
17. Nair V., and Shu Q. Antiviral Chem. Chemother. 18 (2007) 245
18. Pankiewicz K.W., Patterson S.E., Black P.L., Jayaram H.N., Risal D., Goldstein B.M., Stuyver L.J., and Schinazi R.F. Curr. Med. Chem. 11 (2004) 887
19. Sintchak M.D., and Nimmesgern E. Immunopharmacology 47 (2000) 163
20. Merino P., Tejero T., Unzurrunzaga F.J., Franco S., Chiacchio U., Saita M.G., Iannazzo D., Pipernoc A., and Romeo G. Tetrahedron: Asymmetry 16 (2005) 3865
21. Chiacchio U., Rescifina A., Saita M.G., Iannazzo D., Romeo G., Mates J.A., Tejero T., and Merino P. J. Org. Chem. 70 (2005) 8991
22. Chun M.W., Kim M.J., Shin J.H., and Jeong L.S. Nucleosides Nucleotides Nucleic Acids 24 (2005) 975
23. Cai D.-M., Lin K.H., Li M.-Z., Wen J.W., Li H.-Y., and Jou T.-P. Chin. J. Chem. 22 (2005) 1425
24. Nair V., and Wenzel T. ARKIVOC 14 (2004) 128
25. Navarre J.-M., Guianvarc'h D., Farese-Di Giorgio A., Condom R., and Benhida R. Tetrahedron Lett. 44 (2003) 2199
26. Liang C.W., Kim M.J., Jeong L.S., and Chun M.W. Nucleosides Nucleotides Nucleic Acids 22 (2003) 2039
27. Cappellacci L., Barboni G., Franchetti P., Martini C., Jayaram H.N., and Grifantini M. Nucleosides Nucleotides Nucleic Acids 22 (2003) 869
28. Franchetti P., Marchetti S., Cappellacci L., Yalowitz J.A., Jayaram H.N., Goldstein B.M., and Grifantini M. Bioorg. Med. Chem. Lett. 11 (2001) 67
29. Franchetti P., Marchetti S., Cappellacci L., Jayaram H.N., Yalowitz J.A., Goldstein B.M., Barascut J.-L., Dukhan D., Imbach J.-L., and Grifantini M. J. Med. Chem. 43 (2000) 1264
30. Franchetti P., Marchetti S., Cappellacci L., Grifantini M., Goldstein B.M., Dukhan D., Barascut J.-L., and Imbach J.-L. Nucleosides Nucleotides 18 (1999) 679
31. Zhang H.Y., Yu H.W., Ma L.T., Min J.M., and Zhang L.H. Tetrahedron: Asymmetry 9 (1998) 141
32. Franchetti P., Cappellacci L., Abu Seikha G., Jayaram H.N., Gurudutt V.V., Sint T., Schneider B.P., Jones W.D., Goldstein B.M., Perra G., De Montis A., Loi A., La Colla G.P., and Grifantini M. J. Med. Chem. 40 (1997) 1731
33. Franchetti P., Cappellacci L., Grifantini M., Barzi A., Nocentini G., Yang H., O'Conor A., Jayaram H.N., Corell C., and Goldstein B.M. J. Med. Chem. 38 (1995) 3829
34. Popsavin M., Spaić S., Svirčev M., Kojić V., Bogdanović G., and Popsavin V. Bioorg. Med. Chem. Lett. 16 (2006) 5317
35. Popsavin M., Torović Lj., Svirčev M., Kojić V., Bogdanović G., and Popsavin V. Bioorg. Med. Chem. Lett. 16 (2006) 2773
36. Popsavin M., Torović Lj., Kojić V., Bogdanović G., and Popsavin V. Tetrahedron Lett. 45 (2004) 7125
37. Popsavin M., Torović Lj., Kojić V., Bogdanović G., Spaić S., and Popsavin V. Bioorg. Med. Chem. Lett. 13 (2003) 3167
38. Takatsuki K., Ohgushi S., Kohmoto S., Kishikawa K., and Yamamoto M. Nucleosides Nucleotides Nucleic Acids 25 (2006) 719
39. Li Z., Chen S., Jiang N., and Cui G. Nucleosides Nucleotides Nucleic Acids 22 (2003) 419
40. Dyatkina N.B., Atrazheva E.D., Alexandrova L.A., Krayevsky A.A., and von Janta-Lippinsky M. Bioorg. Khim. 14 (1988) 815
41. Webb T.R., Mitsuya H., and Broder S. J. Med. Chem. 31 (1988) 1475
42. For a preliminary account of this work see:. Popsavin M., Spaić S., Svirčev M., Kojić V., Bogdanović G., and Popsavin V. Bioorg. Med. Chem. Lett. 17 (2007) 4123
43. Brown R.S., Dowden J., Moreau C., and Potter B.V.L. Tetrahedron Lett. 43 (2002) 6561
44. Popsavin M., Popsavin V., Vukojević N., Csanádi J., and Miljković D. Carbohydr. Res. 260 (1994) 145
45. Hantzsch A., and Weber J.H. Ber. Dtsch. Chem. Ges. 20 (1887) 3118
46. For a brief review on biological features of l-nucleoside analogues see:. Gumina G., Song G.-Y., and Chu C.K. FEMS Microbiol. Lett. 202 (2001) 9
47. Apart from the isolated products, several more polar components were also detected in the reaction mixture. However, none of these by-products could be obtained in pure form due to their similar chromatographic mobility.
48. For cyanide-catalyzed removal of acetate and benzoate groups in a variety of sugar derivatives, see:
49. Herzig J., Nudelman A., Gottlieb H.E., and Fischer B. J. Org. Chem. 51 (1986) 727
50. Schuerch C., and El-Shenawy H.A. J. Carbohydr. Chem. 4 (1985) 215
51. For application of benzoyl cyanide as benzoylating agent, see:
52. Lin F.L., van Halbeek H., and Bertozzi C.R. Carbohydr. Res. 342 (2007) 2014
53. Prasad A.K., Kumar V., Malhotra S., Ravikumar V.T., Sanghvi Y.S., and Parmar V.S. Bioorg. Med. Chem. 13 (2005) 4467
54. Lay L., Windmuller R., Reinhardt S., and Schmidt R.R. Carbohydr. Res. 303 (1997) 39
55. Holý A., and Souček M. Tetrahedron Lett. (1971) 185
56. 3): δ 3.13 and 3.29 (2×s, 3H each, 2×OMs), 4.36 (m, 1H, H-5), 4.51-4.74 (m, 5H, H-1, H-2 and 2×H-6), 5.35 (dd, 1H, H-3), 5.53 (dd, 1H, H-4), 7.32-8.14 (m, 10H, 2×Ph).
57. Cupps T.L., Wise D.S., and Townsend L.B. J. Org. Chem. 51 (1986) 1058
58. Crystallographic data (excluding structure factors) for the structure 14 have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 706390. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK [fax: +44(0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
59. Sheldrick G.M. Acta Crystallogr. A46 (1990) 467
60. Sheldrick G.M. SHELXL 93, Program for Refinement of Crystal Structures (1993), University of Göttingen, Göttingen
61. Popsavin V., Krstić I., Popsavin M., Srećo B., Benedeković G., Kojić V., and Bogdanović G. Tetrahedron 62 (2006) 11044